<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage - Germans, MR - 2022 | Cochrane Library</title> <meta content="Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage - Germans, MR - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001245.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage - Germans, MR - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001245.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001245.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage" name="citation_title"/> <meta content="Menno R Germans" name="citation_author"/> <meta content="Wouter J Dronkers" name="citation_author"/> <meta content="Merih I Baharoglu" name="citation_author"/> <meta content="RenÃ© Post" name="citation_author"/> <meta content="Dagmar Verbaan" name="citation_author"/> <meta content="Gabriel JE Rinkel" name="citation_author"/> <meta content="University Medical Center Utrecht" name="citation_author_institution"/> <meta content="Yvo BWEM Roos" name="citation_author"/> <meta content="y.b.roos@amsterdamumc.nl" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD001245.pub3" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/11/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001245.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001245.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001245.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Antifibrinolytic Agents [therapeutic use]; *Brain Ischemia; *Hydrocephalus; Persistent Vegetative State [drug therapy]; *Subarachnoid Hemorrhage [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001245.pub3&amp;doi=10.1002/14651858.CD001245.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="KUoIaN9D";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001245\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001245\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001245\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001245\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","ko","ms","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001245.pub3",title:"Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage",firstPublishedDate:"Nov 9, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Stroke Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001245.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001245.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> EspaÃ±ol </option> <option class="content-language-option" data-languagecode="fa" value="fa"> ÙØ§Ø±Ø³Û </option> <option class="content-language-option" data-languagecode="fr" value="fr"> FranÃ§ais </option> <option class="content-language-option" data-languagecode="hi" value="hi"> à¤¹à¤¿à¤¨à¥à¤¦à¥ </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> æ¥æ¬èª </option> <option class="content-language-option" data-languagecode="ko" value="ko"> íêµ­ì´ </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> PortuguÃªs </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Ð ÑÑÑÐºÐ¸Ð¹ </option> <option class="content-language-option" data-languagecode="ro" value="ro"> RomÃ¢nÄ </option> <option class="content-language-option" data-languagecode="ta" value="ta"> à®¤à®®à®¿à®´à¯ </option> <option class="content-language-option" data-languagecode="th" value="th"> à¸ à¸²à¸©à¸²à¹à¸à¸¢ </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> ç¹é«ä¸­æ </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> ç®ä½ä¸­æ </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001245.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001245.pub3/full/es"> EspaÃ±ol </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001245.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001245.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;ÚÚ©ÛØ¯Ù&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;RÃ©sumÃ© scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;ì´ë¡&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;æè¦&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en tÃ©rminos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;Ø®ÙØ§ØµÙ Ø¨Ù Ø²Ø¨Ø§Ù Ø³Ø§Ø¯Ù&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;RÃ©sumÃ© simplifiÃ©&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;ì¬ì´ ë§ ìì½&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Ð ÐµÐ·ÑÐ¼Ðµ Ð½Ð° Ð¿ÑÐ¾ÑÑÐ¾Ð¼ ÑÐ·ÑÐºÐµ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;ç®è¯­æ¦è¦&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;æ·ºé¡¯ææçå£èªçµè«&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001245.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001245.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001245.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001245.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views:Â </span> <span>2955 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001245.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/full#CD001245-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/full#CD001245-sec-0064"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/full#CD001245-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/full#CD001245-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/full#CD001245-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/full#CD001245-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/full#CD001245-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/full#CD001245-sec-0058"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/appendices#CD001245-sec-0069"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/supinfo/CD001245StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/supinfo/CD001245StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright Â© 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/information#CD001245-cr-0004">Menno R Germans</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/information#CD001245-cr-0005">Wouter J Dronkers</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/information#CD001245-cr-0006">Merih I Baharoglu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/information#CD001245-cr-0007">RenÃ© Post</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/information#CD001245-cr-0008">Dagmar Verbaan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/information#CD001245-cr-0009">Gabriel JE Rinkel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001245.pub3/information#CD001245-cr-0010"><i class="icon corresponding-author fa fa-envelope"></i>Yvo BWEM Roos</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/information/en#CD001245-sec-0080">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 November 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001245.pub3">https://doi.org/10.1002/14651858.CD001245.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001245-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001245-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001245-abs-0015">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001245-abs-0011">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001245-abs-0013">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="full/ko#CD001245-abs-0008">íêµ­ì´</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001245-abs-0004">ç®ä½ä¸­æ</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001245-abs-0001" lang="en"> <section id="CD001245-sec-0001"> <h3 class="title" id="CD001245-sec-0001">Background</h3> <p>Rebleeding is an important cause of death and disability in people with aneurysmal subarachnoid haemorrhage. Rebleeding is probably related to the dissolution of the blood clot at the site of the aneurysm rupture by natural fibrinolytic activity. This review is an update of previously published Cochrane Reviews. </p> </section> <section id="CD001245-sec-0002"> <h3 class="title" id="CD001245-sec-0002">Objectives</h3> <p>To assess the effects of antifibrinolytic treatment in people with aneurysmal subarachnoid haemorrhage. </p> </section> <section id="CD001245-sec-0003"> <h3 class="title" id="CD001245-sec-0003">Search methods</h3> <p>We searched the Cochrane Stroke Group Trials Register (May 2022), CENTRAL (in the Cochrane Library 2021, Issue 1), MEDLINE (December 2012 to May 2022), and Embase (December 2012 to May 2022). In an effort to identify further published, unpublished, and ongoing studies, we searched reference lists and trial registers, performed forward tracking of relevant references, and contacted drug companies (the latter in previous versions of this review). </p> </section> <section id="CD001245-sec-0004"> <h3 class="title" id="CD001245-sec-0004">Selection criteria</h3> <p>Randomised trials comparing oral or intravenous antifibrinolytic drugs (tranexamic acid, epsilon aminoâcaproic acid, or an equivalent) with control in people with subarachnoid haemorrhage of suspected or proven aneurysmal cause. </p> </section> <section id="CD001245-sec-0005"> <h3 class="title" id="CD001245-sec-0005">Data collection and analysis</h3> <p>Two review authors (MRG &amp; WJD) independently selected trials for inclusion, and extracted the data for the current update. In total, three review authors (MIB &amp; MRG in the previous update; MRG &amp; WJD in the current update) assessed risk of bias. For the primary outcome, we dichotomised the outcome scales into good and poor outcome, with poor outcome defined as death, vegetative state, or (moderate) severe disability, assessed with either the Glasgow Outcome Scale or the Modified Rankin Scale. We assessed death from any cause, rates of rebleeding, delayed cerebral ischaemia, and hydrocephalus per treatment group. We expressed effects as risk ratios (RR) with 95% confidence intervals (CI). We used randomâeffects models for all analyses. We assessed the quality of the evidence with GRADE. </p> </section> <section id="CD001245-sec-0006"> <h3 class="title" id="CD001245-sec-0006">Main results</h3> <p>We included one new trial in this update, for a total of 11 included trials involving 2717 participants. The risk of bias was low in six studies. Five studies were open label, and we rated them at high risk of performance bias. We also rated one of these studies at high risk for attrition and reporting bias.Â  </p> <p>Five trials reported on poor outcome (death, vegetative state, or (moderate) severe disability), with a pooled risk ratio (RR) of 1.03 (95% confidence interval (CI) 0.94 to 1.13; P = 0.53; 5 trials, 2359 participants; highâquality evidence), which showed no difference between groups. All trials reported on death from all causes, which showed no difference between groups, with a pooled RR of 1.02 (95% CI 0.90 to 1.16; P = 0.77; 11 trials, 2717 participants; highâquality evidence). In trials that combined shortâterm antifibrinolytic treatment (&lt; 72 hours) with preventative measures for delayed cerebral ischaemia, the RR for poor outcome was 0.98 (95% CI 0.81 to 1.18; P = 0.83; 2 trials, 1318 participants; highâquality evidence).Â  </p> <p>Antifibrinolytic treatment reduced the risk of rebleeding, reported at the end of followâup (RR 0.65, 95% CI 0.47 to 0.91; P = 0.01; 11 trials, 2717 participants; absolute risk reduction 7%, 95% CI 3 to 12%; moderateâquality evidence), but there was heterogeneity (IÂ² = 59%) between the trials. The pooled RR for delayed cerebral ischaemia was 1.27 (95% CI 1.00 to 1.62; P = 0.05; 7 trials, 2484 participants; moderateâquality evidence). However, this effect was less extreme after the implementation of ischaemia preventative measures and &lt; 72 hours of treatment (RR 1.10, 95% CI 0.83 to 1.46; P = 0.49; 2 trials, 1318 participants; highâquality evidence). Antifibrinolytic treatment showed no effect on the reported rate of hydrocephalus (RR 1.09, 95% CI 0.99 to 1.20; P = 0.09; 6 trials, 1992 participants; highâquality evidence). </p> </section> <section id="CD001245-sec-0007"> <h3 class="title" id="CD001245-sec-0007">Authors' conclusions</h3> <p>The current evidence does not support the routine use of antifibrinolytic drugs in the treatment of people with aneurysmal subarachnoid haemorrhage. More specifically, early administration with concomitant treatment strategies to prevent delayed cerebral ischaemia does not improve clinical outcome. There is sufficient evidence from multiple randomised controlled trials to incorporate this conclusion in treatment guidelines.Â  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001245-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001245-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001245-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001245-abs-0016">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001245-abs-0012">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001245-abs-0014">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="full/ko#CD001245-abs-0009">íêµ­ì´</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001245-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001245-abs-0007">Ð ÑÑÑÐºÐ¸Ð¹</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001245-abs-0005">ç®ä½ä¸­æ</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD001245-abs-0006">ç¹é«ä¸­æ</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001245-abs-0002" lang="en"> <h3>Drugs for preventing blood clot dissolution (antifibrinolytic therapy) to improve recovery after subarachnoid haemorrhage from a ruptured aneurysm (aneurysmal) </h3> <p><b>Research question</b> </p> <p>What are the effects of antifibrinolytic treatment in people with aneurysmal subarachnoid haemorrhage? </p> <p><b>Background</b> </p> <p>A subarachnoid haemorrhage is bleeding into the small space between the brain and the skull that contains blood vessels that supply the brain (the subarachnoid space). The cause of this type of bleeding is most often a rupture of a weak spot (aneurysm) in one of the brain vessels. A subarachnoid haemorrhage is a relatively uncommon type of stroke, but often occurs at a young age (half the people are younger than 50 years), and therefore, has a significant socioeconomic impact. The outcome following a subarachnoid haemorrhage is often poor; oneâthird of people die after the haemorrhage, and of those who survive, oneâfifth will require help for everyday activities. An important cause of poor recovery after a subarachnoid haemorrhage is repeated (recurrent) bleeding from the aneurysm (rebleeding). This is thought to be caused from natural blood clot dissolving (fibrinolytic) activity. Drugs that reduce the speed of the blood clot dissolving, called antifibrinolytic drugs, were introduced as a treatment to reduce the risk of recurrent bleeding and improve recovery after a subarachnoid haemorrhage. </p> <p><b>Study characteristics</b> </p> <p>The evidence is current to May 2022. This review included 11 trials, with a total of 2717 participants, which investigated the effect of antifibrinolytic drugs in people with a subarachnoid haemorrhage caused by a ruptured aneurysm.Â  </p> <p><b>Key results</b> </p> <p>Antifibrinolytic treatment reduces the risk of rebleeding, but does not improve overall survival, or the chance of being independent in everyday activities. We conclude that there is no evidence to support routinely giving antifibrinolytic treatment to people with a subarachnoid haemorrhage caused by a ruptured aneurysm. </p> <p><b>Quality of evidence</b> </p> <p>We assessed the evidence for the outcomes as moderateâ to highâquality, which means we are very, or moderately confident in the results. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001245-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001245-sec-0064"></div> <h3 class="title" id="CD001245-sec-0065">Implications for practice</h3> <section id="CD001245-sec-0065"> <p>Antifibrinolytic treatment does not improve clinical outcome in people after aneurysmal subarachnoid haemorrhage, although it does reduce the risk of rebleeding. Based on the currently available data, there is no evidence to support routine treatment with antifibrinolytic drugs for people with subarachnoid haemorrhage from a presumed or proven aneurysmal origin. </p> </section> <h3 class="title" id="CD001245-sec-0066">Implications for research</h3> <section id="CD001245-sec-0066"> <p>Over decades, the interval between initial haemorrhage and aneurysm treatment has reduced. This is not only attributable to the improved inâhospital logistics and resources, but also to the earlier diagnosis and shorter transfer time of people to a centre that specialises in aneurysm treatment. The earlier assessment of people with an aneurysmal subarachnoid haemorrhage inherently increases the rebleed rate, because the majority of rebleeds occur in the first hours after the initial haemorrhage. More detailed analysis of the time intervals between initial haemorrhage, start of antifibrinolytic treatment, and aneurysm treatment in relation to rebleeds may reveal a subgroup who could benefit from a reduction in rebleed rate by antifibrinolytic treatment. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001245-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001245-sec-0008"></div> <div class="table" id="CD001245-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign=""> <p><b>Antifibrinolytic therapy compared with standard care for aneurysmal subarachnoid haemorrhage</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Patient or population</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>adults with aneurysmal subarachnoid haemorrhage (SAH)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Setting</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>hospital</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>antifibrinolytic (AF) therapy</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>standard care</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Poor outcome</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.03 (0.94 to 1.13)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2359 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>++++ (high)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At a range of three to six months; low heterogeneity (IÂ² = 0%) between studies and and subgroups </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.02 (0.90 to 1.16)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2717 (11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>++++ (high)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At a range of three weeks to six months; low heterogeneity (IÂ² = 4%) between studies and and subgroups </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rebleeding</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.65 (0.47 to 0.91)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2717 (11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+++ (moderate)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity (IÂ² = 59%) between studies and and subgroups</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Delayed cerebral ischemia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.27 (1.00 to 1.62)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2484 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+++ (moderate)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity (IÂ² = 52%) between studies is largely based on early studies that did not implement ischemia preventive therapy. This resulted in a relatively high OR. Recent studies have implemented ischemia prevention as standard SAH care. It is likely that future research will result in a lower OR for DCI </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hydrocephalus</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.09 (0.99 to 1.20)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1992 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>++++ (high)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low heterogeneity (IÂ² = 0%) between studies and and subgroups</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>DCI</b> : delayed cerebral ischemia; <b>OR</b> : odds ratio; <b>RR:</b> risk ratio </p> <p><sup>a</sup>Quality reduced due to inconsistencies in results<br/><sup>b</sup>Quality reduced due to inconsistency and indirectness </p> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High quality</b>: further research is very unlikely to change our confidence in the estimate of effect. </p> <p><b>Moderate quality</b>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.Â  </p> <p><b>Low quality</b>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> <p><b>Very low quality</b>: we are uncertain about the estimate. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001245-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001245-sec-0009"></div> <section id="CD001245-sec-0010"> <h3 class="title" id="CD001245-sec-0010">Description of the condition</h3> <p>In people with aneurysmal subarachnoid haemorrhage (SAH), rebleeding is a leading cause of death and disability (<a href="./references#CD001245-bbs2-0045" title="RoosYB , deHaanRJ , BeenenLF , GroenRJ , AlbrechtKW , VermeulenM . Complications and outcome in patients with aneurysmal subarachnoid haemorrhage: a prospective hospital based cohort study in the Netherlands. Journal of Neurology, Neurosurgery and Psychiatry2000;68:337-41. [MEDLINE: 10675216]">Roos 2000b</a>;Â <a href="./references#CD001245-bbs2-0046" title="StienenMN , GermansMR , BurkhardtJK , NeidertMC , FungC , BerviniD , et al. Predictors of in-hospital death after aneurysmal subarachnoid hemorrhage: analysis of a nationwide database (Swiss SOS [Swiss Study on Aneurysmal Subarachnoid Hemorrhage]). Stroke2018;49(2):333-40. [DOI: 10.1161/STROKEAHA.117.019328]">Stienen 2018</a>). Without aneurysm treatment, approximately 30% of people with SAH experienced a rebleed within one month of the initial haemorrhage (<a href="./references#CD001245-bbs2-0036" title="LocksleyHB . Natural history of subarachnoid hemorrhage, intracranial aneurysms and arteriovenous malformations. Journal of Neurosurgery1966;25:321-68. [MEDLINE: 1967021605]">Locksley 1966</a>). The rebleeding rate has now been reduced to about 15%, because in most people, the aneurysm is occluded early after admission (<a href="./references#CD001245-bbs2-0029" title="GermansMR , CoertBA , VandertopWP , VerbaanD . Time intervals from subarachnoid hemorrhage to rebleed. Jornal of Neurology2014;261(7):1425-31. [DOI: 10.1007/s00415-014-7365-0]">Germans 2014</a>;Â <a href="./references#CD001245-bbs2-0045" title="RoosYB , deHaanRJ , BeenenLF , GroenRJ , AlbrechtKW , VermeulenM . Complications and outcome in patients with aneurysmal subarachnoid haemorrhage: a prospective hospital based cohort study in the Netherlands. Journal of Neurology, Neurosurgery and Psychiatry2000;68:337-41. [MEDLINE: 10675216]">Roos 2000b</a>). The risk of rebleeding is highest in the first 24 hours after aneurysmal SAH, with more than half of those rebleeds occurring in the first four hours (<a href="./references#CD001245-bbs2-0029" title="GermansMR , CoertBA , VandertopWP , VerbaanD . Time intervals from subarachnoid hemorrhage to rebleed. Jornal of Neurology2014;261(7):1425-31. [DOI: 10.1007/s00415-014-7365-0]">Germans 2014</a>;Â <a href="./references#CD001245-bbs2-0031" title="GuoL , ZhouH , XuJ , WangY , QiuY , JiangJ . Risk factors related to aneurysmal rebleeding. World Neurosurgery2011;76:292-8. [MEDLINE: 21986427]">Guo 2011</a>). The prognosis after rebleeding is poor; approximately 60% of people who rebleed die, and another 30% remain dependent for activities of daily living (<a href="./references#CD001245-bbs2-0040" title="NaidechAM , JanjuaN , KreiterKT , OstapkovichND , FitzsimmonsBF , ParraA , et al. Predictors and impact of aneurysm rebleeding after subarachnoid hemorrhage. Archives of Neurology2005;62:410-6.">Naidech 2005</a>;Â <a href="./references#CD001245-bbs2-0046" title="StienenMN , GermansMR , BurkhardtJK , NeidertMC , FungC , BerviniD , et al. Predictors of in-hospital death after aneurysmal subarachnoid hemorrhage: analysis of a nationwide database (Swiss SOS [Swiss Study on Aneurysmal Subarachnoid Hemorrhage]). Stroke2018;49(2):333-40. [DOI: 10.1161/STROKEAHA.117.019328]">Stienen 2018</a>). </p> </section> <section id="CD001245-sec-0011"> <h3 class="title" id="CD001245-sec-0011">Description of the intervention</h3> <p>Antifibrinolytic drugs have been used to reduce the occurrence of rebleeding for decades, and were first mentioned in 1967 (<a href="./references#CD001245-bbs2-0030" title="GibbsJR , O'GormanP . Fibrinolysis in subarachnoid haemorrhage. Postgraduate Medical Journal1967;43(506):779-84. [MEDLINE: 1968120575]">Gibbs 1967</a>;Â <a href="./references#CD001245-bbs2-0039" title="MullanS , DawleyJ . Antifibrinolytic therapy for intracranial aneurysms. Journal of Neurosurgery1967;28(1):21-3. [DOI: 10.3171/jns.1968.28.1.0021]">Mullan 1967</a>). These drugs are administered orally or intravenously, and block endogenous fibrinolytic activity in the hope of preventing rebleeding. </p> </section> <section id="CD001245-sec-0012"> <h3 class="title" id="CD001245-sec-0012">How the intervention might work</h3> <p>Dissolution of the blood clot at the site of the ruptured aneurysm is thought to be an important factor in the development of rebleeding. This dissolution probably results from endogenous fibrinolytic activity after SAH. Since antifibrinolytic agents reduce fibrinolytic activity, they may reduce the occurrence of rebleeding, and thereby, improve clinical outcome after SAH. However, concerns have been raised that antifibrinolytic therapy may cause an increase of other complications, such as delayed cerebral ischaemia or early brain injury, impeding the recovery from the initial haemorrhage. Delayed cerebral ischaemia is a complication of SAH that occurs in about 30% to 35% of people between 4 and 10 days after SAH. In older trials, the beneficial effect of antifibrinolytic treatment (reducing rebleeding) was offset by an increase in delayed cerebral ischaemia, resulting in a neutral effect on outcome (<a href="./references#CD001245-bbs2-0055" title="BaharogluMI , GermansMR , RinkelGJE , AlgraA , VermeulenM , Van GijnJ , et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhageÂ . Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD001245. [DOI: 10.1002/14651858.CD001245.pub2]">Baharoglu 2013</a>). To reduce this complication, recent literature has been directed more towards shortâterm antifibrinolytic therapy with concomitant preventative measures for the development of delayed cerebral ischaemia, which may prevent the negative effects, but still provide a protective effect for rebleeding. </p> </section> <section id="CD001245-sec-0013"> <h3 class="title" id="CD001245-sec-0013">Why it is important to do this review</h3> <p>In 1967, Gibbs and O'Gorman published the first report on antifibrinolytic treatment in people with SAH (<a href="./references#CD001245-bbs2-0030" title="GibbsJR , O'GormanP . Fibrinolysis in subarachnoid haemorrhage. Postgraduate Medical Journal1967;43(506):779-84. [MEDLINE: 1968120575]">Gibbs 1967</a>). Since then, over 100 studies of antifibrinolytic therapy in aneurysmal SAH have been published. Unfortunately, most of these studies are uncontrolled, and only a minority of the controlled studies are randomised. Moreover, the results of some of the individual randomised studies contradict each other. Furthermore, as mentioned above, concerns have been raised that antifibrinolytic therapy might increase the occurrence of delayed cerebral ischaemia or early brain injury. In a previous version of this review, we found that shortâterm antifibrinolytic treatment in people concomitantly treated with measures to prevent or reverse cerebral ischaemia, may be more effective than the administration regimen in older studies (<a href="./references#CD001245-bbs2-0055" title="BaharogluMI , GermansMR , RinkelGJE , AlgraA , VermeulenM , Van GijnJ , et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhageÂ . Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD001245. [DOI: 10.1002/14651858.CD001245.pub2]">Baharoglu 2013</a>). This led to the hypothesis that when people with aneurysmal SAH are treated according to current guidelines, and with shortâterm antifibrinolytic agents, the beneficial effect of reducing rebleeds is not impeded by complications from the treatment itself. In this update of the 2013 Cochrane Review, we searched for new trials, and gave particular attention to evaluate the effectiveness of shortâterm antifibrinolytic treatment in people concomitantly treated with measures to prevent or reverse delayed cerebral ischaemia (<a href="./references#CD001245-bbs2-0055" title="BaharogluMI , GermansMR , RinkelGJE , AlgraA , VermeulenM , Van GijnJ , et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhageÂ . Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD001245. [DOI: 10.1002/14651858.CD001245.pub2]">Baharoglu 2013</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001245-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001245-sec-0014"></div> <p>To assess the effects of antifibrinolytic treatment in people with aneurysmal subarachnoid haemorrhage. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001245-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001245-sec-0015"></div> <section id="CD001245-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001245-sec-0017"> <h4 class="title">Types of studies</h4> <p>All randomised Â trials in which, after concealed allocation, antifibrinolytic drugs were compared with control treatment (open studies) or placebo (blind studies) in an intentionâtoâtreat analysis.Â  </p> <p>We excluded all trials in which allocation to treatment or control group was not concealed (e.g. trials in which people were allocated by means of an open random number list, alternation, or based on date of birth, days of the week, or hospital number), since foreknowledge of treatment allocation might lead to biased treatment allocation (i.e. selective enrolment). We also excluded trials in which an intentionâtoâtreat analysis was not performed, and could not be reconstructed on the basis of published data without a loss of 20% or more of all randomised participants. </p> </section> <section id="CD001245-sec-0018"> <h4 class="title">Types of participants</h4> <p>Trials in which participants were included with clinical symptoms and signs of subarachnoid haemorrhage (SAH), presumably caused by a ruptured aneurysm, and with confirmation of the diagnosis by the presence of subarachnoid blood on computed tomography (CT) scan, or on cerebrospinal fluid (CSF) examination. </p> </section> <section id="CD001245-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Antifibrinolytic drugs (e.g. tranexamic acid, epsilon aminoâcaproic acid, or equivalent drugs), oral or intravenous, versus control treatment (open studies) or placebo treatment (blind studies). Since the risk of rebleeding is highest during the first two weeks after the initial bleeding, treatment had to start within two weeks after onset of the SAH. Distinction was made between a combination of early start and shortâterm duration(&lt; 72 hours of onset of symptoms, i.e. before usual timing of onset of cerebral ischaemia) versus longâterm (&gt; 72 hours) treatment duration and concomitant measures to prevent delayed cerebral ischaemia or not. </p> </section> <section id="CD001245-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD001245-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome measure was poor outcome (death, vegetative state, or (moderate) severe disability), assessed with either the Glasgow Outcome Scale or the Modified Rankin Scale, at the end of at least three months of followâup after SAH.Â  </p> <p>Death from all causes, at a minimum followâup of at least three weeks, was our second primary outcome, since most studies only reported on case fatality. </p> </section> <section id="CD001245-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcome measures were the effects of antifibrinolytic treatment on both the rates of reported and CT scan, or autopsy confirmed (sensitivity analyses) episodes of rebleeding, delayed cerebral ischaemia, and hydrocephalus. </p> </section> </section> </section> <section id="CD001245-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for trials in all languages, and arranged translations of relevant reports when required. </p> <section id="CD001245-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Stroke Group Trials Register (last searched 31 May 2022), the Cochrane Central Register of Controlled Trials (CENTRAL; 2021, issue 3) in the Cochrane Library (searched 31 May 2022;Â <a href="./appendices#CD001245-sec-0070">Appendix 1</a>), Â MEDLINE Ovid (1946 to 31 May 2022;Â <a href="./appendices#CD001245-sec-0071">Appendix 2</a>), and EMBASE Ovid (1980 to 31 May 2022;Â <a href="./appendices#CD001245-sec-0072">Appendix 3</a>). </p> <p>We developed comprehensive search strategies with the help of the Cochrane Stroke Group Information Specialist, and adapted the MEDLINE strategy for CENTRAL and Embase. Where appropriate, we combined them with subject strategy adaptations of the highly sensitive search strategies, designed by Cochrane to identify RCTs and controlled clinical trials (described in the Technical Supplement to Chapter 4 in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001245-bbs2-0034" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021Â . Available from training.cochrane.org/handbook/archive/v6.2. [www.training.cochrane.org/handbook.]">Lefebvre 2021</a>)). </p> <p>All search strategies were revised and updated to account for newly identified, relevant index headings, and keywords. Both versions of the search strategies are included inÂ <a href="./appendices#CD001245-sec-0073">Appendix 4</a>Â andÂ <a href="./appendices#CD001245-sec-0074">Appendix 5</a>. </p> <p>We also searched the following trial registers for ongoing clinical trials.</p> <p> <ul id="CD001245-list-0001"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 31 May 2022;Â <a href="./appendices#CD001245-sec-0075">Appendix 6</a>) </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://www.trialsearch.who.int" target="_blank">www.trialsearch.who.int</a>; searched 31 May 2022;Â <a href="./appendices#CD001245-sec-0076">Appendix 7</a>) </p> </li> </ul> </p> <p>The following resources were searched for the previous iteration of this review. The EU Clinical Trials Register and ISRCTN data sets are now accessible in the WHO International Clinical Trials Registry Platform; the Stroke Trials Registry site is no longer operational. </p> <p> <ul id="CD001245-list-0002"> <li> <p>EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu" target="_blank">https://www.clinicaltrialsregister.eu</a>; last searched 1 December 2012) </p> </li> <li> <p>Stroke Trials Registry (<a href="http://www.strokecenter.org/trials/" target="_blank">www.strokecenter.org/trials/</a>; last searched 1 December 2012) </p> </li> <li> <p>ISRCTN registry (formerly known as Current Controlled Trials; <a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>; last searched 1 December 2012) </p> </li> </ul> </p> </section> <section id="CD001245-sec-0025"> <h4 class="title">Searching other resources</h4> <p>In an effort to identify further published, unpublished, and ongoing studies:</p> <p> <ul id="CD001245-list-0003"> <li> <p>we searched the list of references quoted in all included studies and reviews on antifibrinolytic therapy (<a href="./references#CD001245-bbs2-0020" title="AdamsHP . Current status of antifibrinolytic therapy for treatment of patients with aneurysmal subarachnoid hemorrhage. Stroke1982;13:256-9. [MEDLINE: 7039006]">Adams 1982</a>;Â <a href="./references#CD001245-bbs2-0021" title="AdamsHP . Antifibrinolytics in aneurysmal subarachnoid hemorrhage. Do they have a role? Maybe. Archives of Neurology1987;44:114-5. [MEDLINE: 3800711]">Adams 1987</a>;Â <a href="./references#CD001245-bbs2-0022" title="BillerJ , GoderskyJC , AdamsHP . Management of aneurysmal subarachnoid hemorrhage. Stroke1988;19:1300-5. [MEDLINE: 3176090]">Biller 1988</a>;Â <a href="./references#CD001245-bbs2-0023" title="CarleyS , SenA . Best evidence topic report. Antifibrinolytics for the initial management of sub arachnoid haemorrhage. Emergency Medicine Journal2005;22:274-5. [MEDLINE: 15788831]">Carley 2005</a>;Â <a href="./references#CD001245-bbs2-0024" title="ChawjolM , StarkeRM , KimGH , MajerSA , ConnollyES . Antifibrinolytic therapy to prevent early rebleeding after subarachnoid hemorrhage. Neurocritical Care2008;8:418-26. [MEDLINE: 18386187]">Chawjol 2008</a>;Â <a href="./references#CD001245-bbs2-0025" title="ConnollyES , RabinsteinAA , CarhuapomaJR , DerdeynCP , DionJ , HigashidaRT , et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2012;43:1711-37. [MEDLINE: 22556195]">Connolly 2012</a>;Â <a href="./references#CD001245-bbs2-0026" title="FodstadH . Antifibrinolytic treatment in subarachnoid haemorrhage: present state. Acta Neurochirurgica1982;63:233-44. [MEDLINE: 1982253415]">Fodstad 1982</a>;Â <a href="./references#CD001245-bbs2-0035" title="LindsayKW . Antifibrinolytic agents in subarachnoid haemorrhage. Journal of Neurology1987;234:1-8. [MEDLINE: 1987140160]">Lindsay 1987</a>;Â <a href="./references#CD001245-bbs2-0037" title="MairaG , AlbaneseA , PentimalliL , TirpakovaB . Treatment of intracranial aneurysms. Clinical and Experimental Hypertension2006;28:371-6. [MEDLINE: 16833048]">Maira 2006</a>;Â <a href="./references#CD001245-bbs2-0038" title="MaybergMR , BatjerHH , DaceyR , DiringerM , HaleyEC , HerosRC , et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Circulation1994;90:2592-605. [MEDLINE: 7955232]">Mayberg 1994</a>;Â <a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>;Â <a href="./references#CD001245-bbs2-0041" title="Ramirez-LassepasM . Antifibrinolytic therapy in subarachnoid hemorrhage caused by ruptured intracranial aneurysm. Neurology1981;31:316-22. [MEDLINE: 1981149246]">Ramirez 1981</a>;Â <a href="./references#CD001245-bbs2-0042" title="RenJ , QianD , WuJ , NiL , QianW , ZhaoG , et al. Safety and efficacy of tranexamic acid in aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials. Forntiers in Neurology2021;12:1-10. [PMID: 35140671]">Ren 2021</a>;Â <a href="./references#CD001245-bbs2-0044" title="RinkelGJ . Medical management of patients with aneurysmal subarachnoid haemorrhage. International Journal of Stroke2008;3:193-204. [MEDLINE: 18705899]">Rinkel 2008</a>;Â <a href="./references#CD001245-bbs2-0047" title="Van GijnJ , RinkelGJ . Subarachnoid haemorrhage: diagnosis, causes and management. Brain2001;124:249-78. [MEDLINE: 11157554]">Van Gijn 2001</a>;Â <a href="./references#CD001245-bbs2-0048" title="Van GijnJ , KerrRS , RinkelGJ . Subarachnoid haemorrhage. Lancet2007;369:306-18. [MEDLINE: 17258671]">Van Gijn 2007</a>;Â <a href="./references#CD001245-bbs2-0050" title="VermeulenM , MuizelaarJP . Do antifibrinolytic agents prevent rebleeding after rupture of a cerebral aneurysm? A review. Clinical Neurology and Neurosurgery1980;82:25-30. [MEDLINE: 1981112901]">Vermeulen 1980</a>;Â <a href="./references#CD001245-bbs2-0052" title="VermeulenM . Subarachnoid haemorrhage: diagnosis and treatment. Journal of Neurology1996;243:496-501. [MEDLINE: 8836937]">Vermeulen 1996</a>;Â <a href="./references#CD001245-bbs2-0053" title="WeaverJP , FisherM . Subarachnoid hemorrhage: an update of pathogenesis, diagnosis and management. Journal of the Neurological Sciences1994;125:119-31. [MEDLINE: 7807157]">Weaver 1994</a>;Â <a href="./references#CD001245-bbs2-0054" title="WeirB . Antifibrinolytics in subarachnoid hemorrhage. Do they have a role? No. Archives of Neurology1987;44:116-8. [MEDLINE: 3800712]">Weir 1987</a>); </p> </li> <li> <p>we used Science Citation Index Cited Reference Search for forward tracking of important articles; and </p> </li> <li> <p>for the first version of this review (<a href="./references#CD001245-bbs2-0056" title="RoosYB , VermeulenM , RinkelGJ , AlgraA , Van GijnJ , AlgraA . Systematic review of antifibrinolytic treatment in aneurysmal subarachnoid haemorrhage. Journal of Neurology, Neurosurgery and Psychiatry1998;65:942-3. [MEDLINE: 9854979]">Roos 1998</a>), we contacted the pharmaceutical company Pharmacia and Upjohn, formerly Kabi, manufacturer and license holder of the antifibrinolytic drug tranexamic acid. We identified no additional (unpublished) studies. </p> </li> </ul> </p> </section> </section> <section id="CD001245-sec-0026"> <h3 class="title" id="CD001245-sec-0026">Data collection and analysis</h3> <section id="CD001245-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MRG and WJD) independently screened the titles and abstracts of the records obtained from the electronic searches and excluded obviously irrelevant records. We obtained the fullâtext articles for the remaining studies, and the same two review authors independently selected the trials that met the predefined inclusion criteria. The review authors resolved disagreements by discussion, and when necessary, in consultation with a third review author (YBWEMR). </p> </section> <section id="CD001245-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (MRG and WJD) independently reviewed the additional eligible studies, and extracted details on the number of participants in the treated and the placebo or control groups, the randomisation method, blinding method, the definitions for diagnosis and complications, and also ascertained whether an intentionâtoâtreat analyses was done or could be reconstructed from the published data. When consensus could not be reached, the review authors consulted a third review author (YBWEMR). </p> </section> <section id="CD001245-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MRG and WD) independently assessed the risk of bias of each additional study using RoB 1, which comprises the criteria outlined in theÂ <i>Cochrane Handbook for Systematic Reviews of Interventions, Chapter 8</i> (<a href="./references#CD001245-bbs2-0032" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/. [URL: www.handbook.cochrane.org]">Higgins 2011</a>). Any disagreements were resolved by discussion. We assessed the risk of bias according to the following domains. </p> <p> <ul id="CD001245-list-0004"> <li> <p>Random sequence generation (selection bias)</p> </li> <li> <p>Allocation concealment (selection bias)</p> </li> <li> <p>Blinding of participants and personnel (performance bias): all outcomes</p> </li> <li> <p>Blinding of outcome assessment (detection bias): all outcomes</p> </li> <li> <p>Incomplete outcome data (attrition bias): all outcomes</p> </li> <li> <p>Selective outcome reporting (reporting bias)</p> </li> <li> <p>Other bias</p> </li> </ul> </p> <p>We graded each potential source of bias as high risk, low risk, or unclear risk of bias,Â and provided information from each study in the risk of bias tables. </p> </section> <section id="CD001245-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We processed data in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions, Chapter 6</i> (<a href="./references#CD001245-bbs2-0033" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook. [URL: www.training.cochrane.org/handbook]">Higgins 2022</a>). For the primary outcome, we dichotomised the outcome scales between good and poor outcome for the analysis. Poor outcome was defined as death, vegetative state, or (moderate) severe disability, as assessed with either the Glasgow Outcome Scale or the modified Rankin Scale. We scored death from any cause, rates of rebleeding, delayed cerebral ischaemia, and hydrocephalus per treatment group. We expressed effects as risk ratios (RR) with 95% confidence intervals (CI). </p> </section> <section id="CD001245-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant, since we only included individually randomised trials with a parallel design. </p> </section> <section id="CD001245-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>In trials without intentionâtoâtreat analysis, we tried to reconstruct one, based only on the published data. When the proportion of missing values for outcome was less than 20%, we included the study in our analysis. For two trials, we tried to contact the principal investigator to retrieve data on the number of participants in whom rebleeding or cerebral ischaemia were proven on CT scan or at autopsy (<a href="./references#CD001245-bbs2-0004" title="HillmanJ , FridrikssonS , NillsonO , YuZ , SavelandH , JakobssonKE . Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. Journal of Neurosurgery2002;97:771-8. [MEDLINE: 12405362]">Hillman 2002</a>;Â <a href="./references#CD001245-bbs2-0009" title="TsementzisSA , HitchcockER , MeyerCH . Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochirurgica1990;102:1-10. [MEDLINE: 1990164043]TsementzisSA , HonanWP , NightingaleS , HitchcockER , MeyerCH . Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid. Acta Neurochirurgica1990;103:116-21. ">Tsementzis 1990</a>). We received a reply from one of the study authors. We made no effort to obtain additional information for studies published 15 or more years ago. </p> </section> <section id="CD001245-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>For each outcome, we assessed statistical heterogeneity using the IÂ²statistic, according to the <i>Cochrane Handbook for Systematic Reviews of Interventions, Chapter 10</i> (<a href="./references#CD001245-bbs2-0033" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook. [URL: www.training.cochrane.org/handbook]">Higgins 2022</a>). We considered an IÂ² statistic less than 50% as low heterogeneity.Â  </p> </section> <section id="CD001245-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>To investigate possible publication bias, we planned to create funnel plots for poor outcome, death from all causes, and the rebleeding rate, if they were measured by at least 10 studies, according to the <i>Cochrane Handbook for Systematic Reviews of Interventions, Chapter 13 (</i><a href="./references#CD001245-bbs2-0033" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook. [URL: www.training.cochrane.org/handbook]">Higgins 2022</a>).Â  </p> </section> <section id="CD001245-sec-0035"> <h4 class="title">Data synthesis</h4> <p>Because we expected heterogeneity between studies, we used Â the MantelâHaenszel randomâeffects model for pooled analyses, in Review Manager software (<a href="./references#CD001245-bbs2-0043" title="Review Manager Web 5 (RevMan Web 5). Version 5.4.1. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">Review Manager Web 2020</a>). </p> </section> <section id="CD001245-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>To assess whether masked studies showed different results from unmasked studies, we divided all analyses into two groups: trials with control treatment (open studies) and trials with placebo treatment (blind studies). We added an additional subgroup analysis to evaluate the effect of antifibrinolytic therapy on all outcomes in trials with and without additional measures to prevent or reverse delayed cerebral ischaemia, and to evaluate the effect of antifibrinolytic therapy according to treatment duration. We divided the included trials into one of three groups: (1) trials without ischaemia prevention and treatment duration &gt; 72 hours, (2) trials with ischaemia prevention and treatment duration &gt; 72 hours, and (3) trials with ischaemia prevention and treatment duration &lt; 72 hours. Because we defined that a minimum of one study should be included in a subgroup, we did not include a fourth group (trials without ischaemia prevention and treatment duration &lt; 72 hours), as there were no trials that met these criteria. </p> <p>In addition, we checked whether data were available on aneurysm treatment (i.e. clipping or coiling) according to antifibrinolytic treatment, to evaluate whether a subgroup analysis on clipping versus coiling was possible. </p> </section> <section id="CD001245-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>Because our secondary outcome measures were more prone to bias, we carried out sensitivity analyses on confirmed (rather than reported) rebleeding, delayed cerebral ischaemia, and hydrocephalus rates. </p> </section> <section id="CD001245-sec-0038"> <h4 class="title">Summary of findings and assessment of the quality of the evidence</h4> <p>We reported the summary of findings according to the <i>Cochrane Handbook for Systematic Reviews of Interventions, Chapter 14</i> (<a href="./references#CD001245-bbs2-0033" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook. [URL: www.training.cochrane.org/handbook]">Higgins 2022</a>). We assessed the quality of the evidence by investigating imprecision by 95% confidence intervals, inconsistency by heterogeneity, indirectness, and study and publication bias by reporting them in risk of bias tables, according to GRADE. Outcomes included poor outcome (death, vegetative state, or (moderate) severe disability), allâcause mortality, rebleeding, delayed cerebral ischaemia, and hydrocephalus. </p> </section> <section id="CD001245-sec-0039"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We reported the summary of findings according to the <i>Cochrane Handbook for Systematic Reviews of Interventions, Chapter 14</i> (<a href="./references#CD001245-bbs2-0033" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook. [URL: www.training.cochrane.org/handbook]">Higgins 2022</a>). We assessed the quality of the evidence by investigating imprecision by 95% confidence intervals, inconsistency by heterogeneity, indirectness, and study and publication bias by reporting them in risk of bias tables according to GRADE. Outcomes included poor outcome (death, vegetative state, or (moderate) severe disability), allâcause mortality, rebleeding, delayed cerebral ischemia, and hydrocephalus. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001245-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001245-sec-0040"></div> <section id="CD001245-sec-0041"> <h3 class="title">Description of studies</h3> <section id="CD001245-sec-0042"> <h4 class="title">Results of the search</h4> <p>The updated 2022 search of the bibliographic databases yielded a total of 1024 records, from which we removed 146 duplicates, leaving a total of 878 records. After screening titles and abstracts, we excluded 872 records, leaving six records for which we obtained the fullâtext articles. Three studies were included in the list of excluded studies in the previous version. Further assessment resulted in one potentially relevant trial (<a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>). Eleven trials met the inclusion criteria for the review; we excluded eight trials. For an overview of the search results, seeÂ <a href="#CD001245-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD001245-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA overview of updated search (December 2012 to May 2022)" data-id="CD001245-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA overview of updated search (December 2012 to May 2022)</p> </div> </div> </div> </section> <section id="CD001245-sec-0043"> <h4 class="title">Included studies</h4> <p>Since the previously published review ofÂ <a href="./references#CD001245-bbs2-0055" title="BaharogluMI , GermansMR , RinkelGJE , AlgraA , VermeulenM , Van GijnJ , et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhageÂ . Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD001245. [DOI: 10.1002/14651858.CD001245.pub2]">Baharoglu 2013</a>,Â one new trial met the inclusion criteria (<a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>). Therefore, we included 11 studies, which are described in detail in theÂ <a href="./references#CD001245-sec-0086" title="">Characteristics of included studies</a>Â table (<a href="./references#CD001245-bbs2-0001" title="ChandraB . Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. Annals of Neurology1978;3:502-4. [MEDLINE: 1978233972]">Chandra 1978</a>;Â <a href="./references#CD001245-bbs2-0002" title="FodstadH , ForssellA , LiliequistB , SchannongM . Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. Neurosurgery1981;8:158-65. [MEDLINE: 1981149180]">Fodstad 1981</a>;Â <a href="./references#CD001245-bbs2-0003" title="GirvinJP . The use of antifibrinolytic agents in the preoperative treatment of ruptured intracranial aneurysms. Transactions of the American Neurological Association1973;98:150-2. [MEDLINE: 1974127393]">Girvin 1973</a>;Â <a href="./references#CD001245-bbs2-0004" title="HillmanJ , FridrikssonS , NillsonO , YuZ , SavelandH , JakobssonKE . Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. Journal of Neurosurgery2002;97:771-8. [MEDLINE: 12405362]">Hillman 2002</a>;Â <a href="./references#CD001245-bbs2-0005" title="KasteM , RamsayM . Tranexamic acid in subarachnoid hemorrhage. A double-blind study. Stroke1979;10:519-22. [MEDLINE: 1980059548]">Kaste 1979</a>;Â <a href="./references#CD001245-bbs2-0006" title="Maurice-WilliamsRS . Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms?British Medical Journal1978;1:945-7. [MEDLINE: 1978145585]">Maurice 1978</a>;Â <a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>;Â <a href="./references#CD001245-bbs2-0008" title="RoosY , for the STAR-study group. Antifibrinolytic treatment in aneurysmal subarachnoid haemorrhage: a randomized placebo-controlled trial. Neurology2000;54:77-82. [MEDLINE: 10636129]">Roos 2000a</a>;Â <a href="./references#CD001245-bbs2-0009" title="TsementzisSA , HitchcockER , MeyerCH . Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochirurgica1990;102:1-10. [MEDLINE: 1990164043]TsementzisSA , HonanWP , NightingaleS , HitchcockER , MeyerCH . Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid. Acta Neurochirurgica1990;103:116-21. ">Tsementzis 1990</a>;Â <a href="./references#CD001245-bbs2-0010" title="Van RossumJ , WintzenAR , EndtzLJ , SchoenJH , deJongeH . Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial. Annals of Neurology1977;2:238-42. [MEDLINE: 1979081173]">Van Rossum 1977</a>;Â <a href="./references#CD001245-bbs2-0011" title="VermeulenM , LindsayKW , MurrayGD , CheahF , HijdraA , MuizelaarJP , et al. Antifibrinolytic treatment in subarachnoid hemorrhage. New England Journal of Medicine1984;311:432-7. [MEDLINE: 1984270539]">Vermeulen 1984</a>). These 11 studies included 2717 participants, 1368 of whom were randomised to receive antifibrinolytic drugs, 597 to receive placebo treatment, and 752 to receive control treatment. TheÂ <a href="./references#CD001245-bbs2-0003" title="GirvinJP . The use of antifibrinolytic agents in the preoperative treatment of ruptured intracranial aneurysms. Transactions of the American Neurological Association1973;98:150-2. [MEDLINE: 1974127393]">Girvin 1973</a>Â study used epsilonâaminoâcaproic acid (39 participants); tranexamic acid was used in all other studies. The <a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a> studyÂ is the largest trial, including 955 participants; however, the study also included participants with nonâaneurysmal SAH (14%). The data for the current review were extracted from <a href="./references#CD001245-bbs2-0009" title="TsementzisSA , HitchcockER , MeyerCH . Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochirurgica1990;102:1-10. [MEDLINE: 1990164043]TsementzisSA , HonanWP , NightingaleS , HitchcockER , MeyerCH . Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid. Acta Neurochirurgica1990;103:116-21. ">Tsementzis 1990</a>, which only presented the results of the aneurysmal SAH (<a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>). In three studies, participants were concomitantly treated with measures to prevent or reverse cerebral ischaemia (<a href="./references#CD001245-bbs2-0004" title="HillmanJ , FridrikssonS , NillsonO , YuZ , SavelandH , JakobssonKE . Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. Journal of Neurosurgery2002;97:771-8. [MEDLINE: 12405362]">Hillman 2002</a>;Â <a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>;Â <a href="./references#CD001245-bbs2-0008" title="RoosY , for the STAR-study group. Antifibrinolytic treatment in aneurysmal subarachnoid haemorrhage: a randomized placebo-controlled trial. Neurology2000;54:77-82. [MEDLINE: 10636129]">Roos 2000a</a>). The duration of antifibrinolytic treatment differed considerably between studies, and ranged from less than 72 hours to six weeks. Shortâterm treatment was used in two studies (<a href="./references#CD001245-bbs2-0004" title="HillmanJ , FridrikssonS , NillsonO , YuZ , SavelandH , JakobssonKE . Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. Journal of Neurosurgery2002;97:771-8. [MEDLINE: 12405362]">Hillman 2002</a>;Â <a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>). In these studies, participants were treated up to 72 hours after SAH (<a href="./references#CD001245-bbs2-0004" title="HillmanJ , FridrikssonS , NillsonO , YuZ , SavelandH , JakobssonKE . Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. Journal of Neurosurgery2002;97:771-8. [MEDLINE: 12405362]">Hillman 2002</a>), or up to 24 hours after the start of tranexamic acid treatment (<a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>). All other studies treated participants for at least 10 days (or until occlusion of the aneurysm) after SAH. </p> <p>Five studies reported clinical outcome, and we were able to reconstruct the number of participants with poor outcomes (<a href="./references#CD001245-bbs2-0004" title="HillmanJ , FridrikssonS , NillsonO , YuZ , SavelandH , JakobssonKE . Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. Journal of Neurosurgery2002;97:771-8. [MEDLINE: 12405362]">Hillman 2002</a>;Â <a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>;Â <a href="./references#CD001245-bbs2-0008" title="RoosY , for the STAR-study group. Antifibrinolytic treatment in aneurysmal subarachnoid haemorrhage: a randomized placebo-controlled trial. Neurology2000;54:77-82. [MEDLINE: 10636129]">Roos 2000a</a>;Â <a href="./references#CD001245-bbs2-0009" title="TsementzisSA , HitchcockER , MeyerCH . Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochirurgica1990;102:1-10. [MEDLINE: 1990164043]TsementzisSA , HonanWP , NightingaleS , HitchcockER , MeyerCH . Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid. Acta Neurochirurgica1990;103:116-21. ">Tsementzis 1990</a>;Â <a href="./references#CD001245-bbs2-0011" title="VermeulenM , LindsayKW , MurrayGD , CheahF , HijdraA , MuizelaarJP , et al. Antifibrinolytic treatment in subarachnoid hemorrhage. New England Journal of Medicine1984;311:432-7. [MEDLINE: 1984270539]">Vermeulen 1984</a>). Death from all causes and rebleeding rates were reported in all 11 studies. In six studies, episodes of rebleeding were defined primarily by clinical symptoms. </p> <p>Three trials reported computed tomography (CT) scanâ or autopsyâconfirmed episodes of rebleeding (<a href="./references#CD001245-bbs2-0002" title="FodstadH , ForssellA , LiliequistB , SchannongM . Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. Neurosurgery1981;8:158-65. [MEDLINE: 1981149180]">Fodstad 1981</a>;Â <a href="./references#CD001245-bbs2-0004" title="HillmanJ , FridrikssonS , NillsonO , YuZ , SavelandH , JakobssonKE . Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. Journal of Neurosurgery2002;97:771-8. [MEDLINE: 12405362]">Hillman 2002</a>;Â <a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>). Three trials defined and reported rebleeding in two ways: as 'probable' if the diagnosis was suspected solely on clinical grounds, and as 'definite' when proven by CT (after comparison with an earlier CT), or at autopsy; the DutchâBritish trial (<a href="./references#CD001245-bbs2-0011" title="VermeulenM , LindsayKW , MurrayGD , CheahF , HijdraA , MuizelaarJP , et al. Antifibrinolytic treatment in subarachnoid hemorrhage. New England Journal of Medicine1984;311:432-7. [MEDLINE: 1984270539]">Vermeulen 1984</a>), STAR study (<a href="./references#CD001245-bbs2-0008" title="RoosY , for the STAR-study group. Antifibrinolytic treatment in aneurysmal subarachnoid haemorrhage: a randomized placebo-controlled trial. Neurology2000;54:77-82. [MEDLINE: 10636129]">Roos 2000a</a>), and the ULTRA trial (<a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>). </p> <p>Delayed cerebral ischaemia was reported in seven studies, but defined in only four: in two studies, cerebral ischaemia was defined and reported in the same manner as episodes of rebleeding; as 'probable' and as 'definite' (CT scanâ or autopsyâconfirmed) cerebral ischaemia (<a href="./references#CD001245-bbs2-0008" title="RoosY , for the STAR-study group. Antifibrinolytic treatment in aneurysmal subarachnoid haemorrhage: a randomized placebo-controlled trial. Neurology2000;54:77-82. [MEDLINE: 10636129]">Roos 2000a</a>;Â <a href="./references#CD001245-bbs2-0011" title="VermeulenM , LindsayKW , MurrayGD , CheahF , HijdraA , MuizelaarJP , et al. Antifibrinolytic treatment in subarachnoid hemorrhage. New England Journal of Medicine1984;311:432-7. [MEDLINE: 1984270539]">Vermeulen 1984</a>). Again, as for rebleeding,Â <a href="./references#CD001245-bbs2-0002" title="FodstadH , ForssellA , LiliequistB , SchannongM . Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. Neurosurgery1981;8:158-65. [MEDLINE: 1981149180]">Fodstad 1981</a>Â reported on CT scanâ or autopsyâconfirmed cerebral ischaemia.Â <a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>Â defined delayed cerebral ischaemia according to the definition used by a multidisciplinary research group (<a href="./references#CD001245-bbs2-0049" title="VergouwenMD , VermeulenM , vanGijnJ , RinkelGJ , WijdicksEF , MuizelaarJP , et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke2010;41(10):2391-5. [DOI: 10.1161/STROKEAHA.110.589275]">Vergouwen 2010</a>).Â <a href="./references#CD001245-bbs2-0004" title="HillmanJ , FridrikssonS , NillsonO , YuZ , SavelandH , JakobssonKE . Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. Journal of Neurosurgery2002;97:771-8. [MEDLINE: 12405362]">Hillman 2002</a>Â reported the percentage of transient and permanent delayed ischaemic neurological deficits. No clear definition was given, and CT scans were not routinely used to confirm delayed cerebral ischaemia. Because other studies did not make a distinction between permanent or transient delayed cerebral ischaemia, we decided to combine these outcomes.Â <a href="./references#CD001245-bbs2-0004" title="HillmanJ , FridrikssonS , NillsonO , YuZ , SavelandH , JakobssonKE . Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. Journal of Neurosurgery2002;97:771-8. [MEDLINE: 12405362]">Hillman 2002</a>Â reported visible infarction on CT scan; however, after contact with the study author, we decided not to use this as a measure for delayed cerebral ischaemia, since this was not always correlated to clinical signs of delayed cerebral ischaemia. The other two studies made no distinction between participants with episodes clinically suggestive of delayed cerebral ischaemia, or participants with confirmed delayed cerebral ischaemia, and reported only an allâinclusive number of participants (<a href="./references#CD001245-bbs2-0003" title="GirvinJP . The use of antifibrinolytic agents in the preoperative treatment of ruptured intracranial aneurysms. Transactions of the American Neurological Association1973;98:150-2. [MEDLINE: 1974127393]">Girvin 1973</a>;Â <a href="./references#CD001245-bbs2-0009" title="TsementzisSA , HitchcockER , MeyerCH . Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochirurgica1990;102:1-10. [MEDLINE: 1990164043]TsementzisSA , HonanWP , NightingaleS , HitchcockER , MeyerCH . Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid. Acta Neurochirurgica1990;103:116-21. ">Tsementzis 1990</a>). One study reported on 'delayed cerebral ischaemia' and 'postoperative ischaemia' (<a href="./references#CD001245-bbs2-0008" title="RoosY , for the STAR-study group. Antifibrinolytic treatment in aneurysmal subarachnoid haemorrhage: a randomized placebo-controlled trial. Neurology2000;54:77-82. [MEDLINE: 10636129]">Roos 2000a</a>). Since the other studies did not make this distinction, and reported an overall number of participants with delayed cerebral ischaemia, we grouped these subgroups of ischaemia for the analysis on cerebral ischaemia. </p> <p>Six trials reported on hydrocephalus. Hydrocephalus was defined in two studies by means other than clinical grounds, and therefore, could be included in the sensitivity analysis for confirmed hydrocephalus (<a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>;Â <a href="./references#CD001245-bbs2-0008" title="RoosY , for the STAR-study group. Antifibrinolytic treatment in aneurysmal subarachnoid haemorrhage: a randomized placebo-controlled trial. Neurology2000;54:77-82. [MEDLINE: 10636129]">Roos 2000a</a>). No trials reported on aneurysm treatment modality (i.e. coiling versus clipping) according to antifibrinolytic or control treatment, and thus, we were unable to undertake a subgroup analysis based on aneurysmal occlusion modality.Â  </p> </section> <section id="CD001245-sec-0044"> <h4 class="title">Excluded studies</h4> <p>We excluded eight studies (seeÂ <a href="./references#CD001245-sec-0087" title="">Characteristics of excluded studies</a> table): some were comparative trials between two or more antifibrinolytic agents, others used unconcealed allocation, and some were not randomised but used historical controls. We excludedÂ <a href="./references#CD001245-bbs2-0018" title="FodstadH , LiliequistB , SchannongM , ThulinCA . Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. Surgical Neurology1978;10:9-15. [MEDLINE: 1978250737]">Fodstad 1978</a>,Â as 23% of the participants in the trial were later excluded, and we were unable to reconstruct an intentionâtoâtreat analysis on the basis of the published data. </p> </section> </section> <section id="CD001245-sec-0045"> <h3 class="title">Risk of bias in included studies</h3> <p>For a summary of the risk of bias seeÂ <a href="#CD001245-fig-0002">Figure 2</a>Â andÂ <a href="#CD001245-fig-0003">Figure 3</a>. Six of the 11 included trials used an intentionâtoâtreat analysis; in one of the remaining trials, we were unable to reconstruct this analysis using the available followâup data (<a href="./references#CD001245-bbs2-0006" title="Maurice-WilliamsRS . Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms?British Medical Journal1978;1:945-7. [MEDLINE: 1978145585]">Maurice 1978</a>). </p> <div class="figure" id="CD001245-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD001245-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="figure" id="CD001245-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD001245-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD001245-sec-0046"> <h4 class="title">Allocation</h4> <p><a href="./references#CD001245-bbs2-0003" title="GirvinJP . The use of antifibrinolytic agents in the preoperative treatment of ruptured intracranial aneurysms. Transactions of the American Neurological Association1973;98:150-2. [MEDLINE: 1974127393]">Girvin 1973</a>Â used 'flipâofâaâcoin' randomisation as the method of allocation, which is more susceptible to bias compared with, for instance, the sealed envelope method. Nevertheless, we decided to include this study, since this is an accepted form of randomisation with allocation sequence generation and concealment according to Cochrane guidelines. All other studies used a method of concealed allocation that was considered appropriate at the time the trial was conducted, although it was not always mentioned whether or not the sealed envelopes that were used were opaque, resulting in an unclear risk of bias assessment (<a href="./references#CD001245-bbs2-0002" title="FodstadH , ForssellA , LiliequistB , SchannongM . Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. Neurosurgery1981;8:158-65. [MEDLINE: 1981149180]">Fodstad 1981</a>;Â <a href="./references#CD001245-bbs2-0004" title="HillmanJ , FridrikssonS , NillsonO , YuZ , SavelandH , JakobssonKE . Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. Journal of Neurosurgery2002;97:771-8. [MEDLINE: 12405362]">Hillman 2002</a>). </p> </section> <section id="CD001245-sec-0047"> <h4 class="title">Blinding</h4> <p>Six studies used a doubleâblind method (placebo controlled), and five used a control group with standard treatment without placebo. The control group studies were open label, and we rated them at high risk of performance bias (all five studies), and detection bias (one study:Â <a href="./references#CD001245-bbs2-0004" title="HillmanJ , FridrikssonS , NillsonO , YuZ , SavelandH , JakobssonKE . Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. Journal of Neurosurgery2002;97:771-8. [MEDLINE: 12405362]">Hillman 2002</a>). </p> </section> <section id="CD001245-sec-0048"> <h4 class="title">Incomplete outcome data</h4> <p>In five trials, there was no followâup information available for participants who were excluded after randomisation (<a href="./references#CD001245-bbs2-0002" title="FodstadH , ForssellA , LiliequistB , SchannongM . Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. Neurosurgery1981;8:158-65. [MEDLINE: 1981149180]">Fodstad 1981</a>;Â <a href="./references#CD001245-bbs2-0004" title="HillmanJ , FridrikssonS , NillsonO , YuZ , SavelandH , JakobssonKE . Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. Journal of Neurosurgery2002;97:771-8. [MEDLINE: 12405362]">Hillman 2002</a>;Â <a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>;Â <a href="./references#CD001245-bbs2-0009" title="TsementzisSA , HitchcockER , MeyerCH . Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochirurgica1990;102:1-10. [MEDLINE: 1990164043]TsementzisSA , HonanWP , NightingaleS , HitchcockER , MeyerCH . Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid. Acta Neurochirurgica1990;103:116-21. ">Tsementzis 1990</a>;Â <a href="./references#CD001245-bbs2-0010" title="Van RossumJ , WintzenAR , EndtzLJ , SchoenJH , deJongeH . Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial. Annals of Neurology1977;2:238-42. [MEDLINE: 1979081173]">Van Rossum 1977</a>). In four studies, a very small number of participants were excluded from the final analysis (<a href="./references#CD001245-bbs2-0002" title="FodstadH , ForssellA , LiliequistB , SchannongM . Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. Neurosurgery1981;8:158-65. [MEDLINE: 1981149180]">Fodstad 1981</a> (n = 1);Â <a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a> (n = 10);Â <a href="./references#CD001245-bbs2-0009" title="TsementzisSA , HitchcockER , MeyerCH . Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochirurgica1990;102:1-10. [MEDLINE: 1990164043]TsementzisSA , HonanWP , NightingaleS , HitchcockER , MeyerCH . Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid. Acta Neurochirurgica1990;103:116-21. ">Tsementzis 1990</a> (n = 4);Â <a href="./references#CD001245-bbs2-0010" title="Van RossumJ , WintzenAR , EndtzLJ , SchoenJH , deJongeH . Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial. Annals of Neurology1977;2:238-42. [MEDLINE: 1979081173]">Van Rossum 1977</a> (n = 3); therefore, we still included these studies.Â  </p> <p>In one study, 91 (15%) of the 596 participants were excluded after randomisation (<a href="./references#CD001245-bbs2-0004" title="HillmanJ , FridrikssonS , NillsonO , YuZ , SavelandH , JakobssonKE . Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. Journal of Neurosurgery2002;97:771-8. [MEDLINE: 12405362]">Hillman 2002</a>). Because this was less than the prespecified proportion of 20%, we included this study in our analysis. We rated this study at high risk of bias for incomplete outcome data (attrition bias). </p> </section> <section id="CD001245-sec-0049"> <h4 class="title">Selective reporting</h4> <p>In one study, no previously published protocol was mentioned, and clinical outcome was reported, although not described, in the introduction or methods Â (<a href="./references#CD001245-bbs2-0004" title="HillmanJ , FridrikssonS , NillsonO , YuZ , SavelandH , JakobssonKE . Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. Journal of Neurosurgery2002;97:771-8. [MEDLINE: 12405362]">Hillman 2002</a>). For the <a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a> study, a protocol was published (<a href="./references#CD001245-bbs2-0028" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]">Germans 2013</a>). The primary outcome and most secondary outcomes were reported, including all secondary outcomes relevant to this review. In two other studies, the selective reporting could not be assessed, and we reported them as unclear risk of bias (<a href="./references#CD001245-bbs2-0001" title="ChandraB . Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. Annals of Neurology1978;3:502-4. [MEDLINE: 1978233972]">Chandra 1978</a>; <a href="./references#CD001245-bbs2-0009" title="TsementzisSA , HitchcockER , MeyerCH . Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochirurgica1990;102:1-10. [MEDLINE: 1990164043]TsementzisSA , HonanWP , NightingaleS , HitchcockER , MeyerCH . Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid. Acta Neurochirurgica1990;103:116-21. ">Tsementzis 1990</a>). </p> </section> <section id="CD001245-sec-0050"> <h4 class="title">Other potential sources of bias</h4> <p>No studies showed a high risk of other source of bias, however, in four studies, we could not assess this, and therefore, we reported them as unclear risk of bias (<a href="./references#CD001245-bbs2-0001" title="ChandraB . Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. Annals of Neurology1978;3:502-4. [MEDLINE: 1978233972]">Chandra 1978</a>;Â <a href="./references#CD001245-bbs2-0005" title="KasteM , RamsayM . Tranexamic acid in subarachnoid hemorrhage. A double-blind study. Stroke1979;10:519-22. [MEDLINE: 1980059548]">Kaste 1979</a>;Â <a href="./references#CD001245-bbs2-0006" title="Maurice-WilliamsRS . Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms?British Medical Journal1978;1:945-7. [MEDLINE: 1978145585]">Maurice 1978</a>;Â <a href="./references#CD001245-bbs2-0009" title="TsementzisSA , HitchcockER , MeyerCH . Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochirurgica1990;102:1-10. [MEDLINE: 1990164043]TsementzisSA , HonanWP , NightingaleS , HitchcockER , MeyerCH . Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid. Acta Neurochirurgica1990;103:116-21. ">Tsementzis 1990</a>). The funnel plots for death and rebleeding are shown inÂ <a href="#CD001245-fig-0004">Figure 4</a>Â andÂ <a href="#CD001245-fig-0005">Figure 5</a>. The plot on 'poor outcome'Â (<a href="#CD001245-fig-0005">Figure 5</a>),Â shows no asymmetry and heterogeneity was low between studies, indicating no publication bias.Â  </p> <div class="figure" id="CD001245-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of included trials assessing case fatality" data-id="CD001245-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of included trials assessing case fatality</p> </div> </div> </div> <div class="figure" id="CD001245-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of included trials assessing rebleeding" data-id="CD001245-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of included trials assessing rebleeding</p> </div> </div> </div> </section> </section> <section id="CD001245-sec-0051"> <h3 class="title" id="CD001245-sec-0051">Effects of interventions</h3> <p>See: <a href="./full#CD001245-tbl-0001"><b>Summary of findings 1</b> Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage</a> </p> <section id="CD001245-sec-0052"> <h4 class="title">Antifibrinolytic treatment versus control treatment with or without placebo</h4> <section id="CD001245-sec-0053"> <h5 class="title">Poor outcome</h5> <p>The results were inconclusive for poor outcome (risk ratio (RR) 1.03, 95% confidence interval (CI) 0.94 to 1.13; P = 0.53; 5 trials, 2359 participants; highâquality evidence;Â <a href="./references#CD001245-fig-0006" title="">Analysis 1.1</a>). The results remained inconclusive when analysed by duration of treatment (P = 0.83;Â <a href="./references#CD001245-fig-0007" title="">Analysis 1.2</a>). </p> </section> <section id="CD001245-sec-0054"> <h5 class="title">Allâcause mortality</h5> <p>The pooled RR for our second primary outcome measure, allâcause Â mortality, was 1.02 (95% CI 0.90 to 1.16; P = 0.77; 11 trials, 2717 participants; highâquality evidence;Â <a href="./references#CD001245-fig-0008" title="">Analysis 1.3</a>). Duration of treatment showed no effect on allâcause mortality (P = 0.77;Â <a href="./references#CD001245-fig-0009" title="">Analysis 1.4</a>). </p> </section> <section id="CD001245-sec-0055"> <h5 class="title">Confirmed rebleeding</h5> <p>In the analysis on rebleeding rates, antifibrinolytic therapy reduced the risk of rebleeding (RR 0.65, 95% CI 0.47 to 0.91; P = 0.01; 11 trials, 2717 participants; moderateâquality evidence; absolute risk reduction 7%, 95% CI 3 to 12%;Â <a href="./references#CD001245-fig-0010" title="">Analysis 1.5</a>). Heterogeneity was detected for this comparison (IÂ² = 59%; P = 0.007;Â <a href="./references#CD001245-fig-0010" title="">Analysis 1.5</a>). Similar estimates were found in the subgroup analysis of the six doubleâblind and placeboâcontrolled studies (RR 0.64; P = 0.03;Â <a href="./references#CD001245-fig-0010" title="">Analysis 1.5</a>); the sensitivity analysis including five studies with CT scanâ or autopsyâconfirmed rebleeding (RR 0.50; P &lt; 0.001;Â <a href="./references#CD001245-fig-0011" title="">Analysis 1.6</a>); and in the subgroup analysis of two studies with ischaemia prevention and &lt; 72 hours of treatment (RR 0.42; P = 0.14;Â <a href="./references#CD001245-fig-0012" title="">Analysis 1.7</a>). </p> </section> <section id="CD001245-sec-0056"> <h5 class="title">Delayed cerebral ischaemia</h5> <p>Seven trials that reported delayed cerebral ischaemia rates showed moderateâquality evidence that antifibrinolytic treatment increased the risk of delayed cerebral ischaemia (RR 1.27, 95% CI 1.00 to 1.62; P = 0.05; 7 trials, 2484 participants; moderateâquality evidence; absolute increase of 36 per 1000 people;Â <a href="./references#CD001245-fig-0013" title="">Analysis 1.8</a>). Similar effects were seen in the subgroup analysis of the three placeboâcontrolled trials (RR 1.38; P = 0.17;Â <a href="./references#CD001245-fig-0013" title="">Analysis 1.8</a>). This effect was reduced, and showed no association after the implementation of ischaemia preventative measures and &lt; 72 hours of treatment (RR 1.10; P = 0.49;Â <a href="./references#CD001245-fig-0015" title="">Analysis 1.10</a>).Â Heterogeneity of intervention effect was detected in all seven studies combined (IÂ² = 52%; P = 0.05;Â <a href="./references#CD001245-fig-0015" title="">Analysis 1.10</a>). This effect was reduced in the two trials with ischaemia prevention and treatment &lt; 72 hours, with low heterogeneity (IÂ² = 35%; P = 0.49;Â <a href="./references#CD001245-fig-0015" title="">Analysis 1.10</a>).Â  </p> </section> <section id="CD001245-sec-0057"> <h5 class="title">Hydrocephalus</h5> <p>Hydrocephalus was reported in six trials. Overall, antifibrinolytic treatment had no effect on the reported rates of hydrocephalus (RR 1.09, 95% CI 0.99 to 1.20; P = 0.09; 6 trials, 1992 participants; highâquality evidence;Â <a href="./references#CD001245-fig-0016" title="">Analysis 1.11</a>). In the subgroup analysis on placebo versus open studies, antifibrinolytic treatment in the placebo controlled studies showed a more pronounced effect for hydrocephalus (RR 1.19; P = 0.13;Â <a href="./references#CD001245-fig-0016" title="">Analysis 1.11</a>), whereas in the open label trials, it was more protective for hydrocephalus (RR 0.94; P = 0.73;Â <a href="./references#CD001245-fig-0016" title="">Analysis 1.11</a>). The sensitivity analysis on two trials with CT scanâ or autopsyâconfirmed hydrocephalus, including 93% of all hydrocephalus patients, showed no association between antifibrinolytic treatment and hydrocephalus (RR 1.09, 95% CI 0.99 to 1.21; P = 0.09; 2 trials, 1275 participants;Â <a href="./references#CD001245-fig-0017" title="">Analysis 1.12</a>). Ischaemia prevention did not seem to have any effect on hydrocephalus in the subgroup analyses (P = 0.85;Â <a href="./references#CD001245-fig-0018" title="">Analysis 1.13</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001245-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001245-sec-0058"></div> <section id="CD001245-sec-0059"> <h3 class="title" id="CD001245-sec-0059">Summary of main results</h3> <p>Although this systematic review and metaâanalysis show that antifibrinolytic treatment reduces the rate of rebleeding by approximately 35%, there is no evidence of benefit from antifibrinolytic treatment on poor outcome or death from all causes. We added the recent and largest ULTRA trial, which administered antifibrinolytic treatment ultraâearly and shortâterm, to the review, but there was no change in the overall conclusion compared to previous versions (<a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>). A sensitivity analysis on trials with ischaemia prevention and shortâterm (&lt; 72 hours) antifibrinolytic treatment did not show a difference in the effect on either poor outcome, or death from all causes. Furthermore, the risk for delayed cerebral ischaemia was not increased by antifibrinolytic treatment when ischaemia preventative measures were applied. The current, highâquality evidence does not support the routine use of antifibrinolytic treatment in people with aneurysmal subarachnoid haemorrhage. </p> </section> <section id="CD001245-sec-0060"> <h3 class="title" id="CD001245-sec-0060">Overall completeness and applicability of evidence</h3> <p>Trials in which people were included with symptoms and signs of subarachnoid haemorrhage (SAH) of suspected or proven aneurysmal cause, with confirmation of the diagnosis by the presence of subarachnoid blood on computed tomography (CT) or on cerebrospinal fluid (CSF) examination were eligible for this review. We chose this pragmatic approach, and did not restrict our review to people with angiographicallyâproven aneurysms, because antifibrinolytic treatment may also be started after CT angiography (CTA)âconfirmed presence of an intracranial aneurysm. However, we chose not to limit our analysis to radiologicallyâproven aneurysmal SAH, because CTA was not regularly applied when most of the trials were conducted. In the past decades, the outcome of aneurysmal SAH has constantly improved, which is attributable to improved intensive care management, aneurysm treatment techniques, and reduced interval to aneurysm treatment. Especially, earlier aneurysm treatment may have had influence on a reduced incidence of rebleeds, diminishing the potential effect of reducing rebleeds by antifibrinolytic treatment. Nevertheless, the evidence undisputedly shows that despite a significant reduction in rebleeds, the overall outcome is not improved with antifibrinolytic therapy. However, the current evidence is unclear about the effect of antifibrinolytic treatment in a subgroup of people at a very high risk for rebleeding, such as those who are diagnosed very early, or in those for whom there is anticipated delay in aneurysm treatment.Â  </p> <p>The included trials were performed in a timespan of 48 years, during which overall clinical outcome has improved. Treating people with aneurysmal SAH with preventative measures for delayed cerebral ischaemia has eliminated the increased risk of this complication of antifibrinolytic treatment. Even then, antifibrinolytic treatment does not improve poor outcome or death from all causes. The consistency of results in several studies with low risks of bias, and persistency over years even with optimisation of the treatment of complications, makes this conclusion generalisable. It is very unlikely that future trials will change the conclusion that routine antifibrinolytic treatment has no evidence of benefit in people with aneurysmal subarachnoid haemorrhage.Â  </p> </section> <section id="CD001245-sec-0061"> <h3 class="title" id="CD001245-sec-0061">Quality of the evidence</h3> <p>We only included true randomised controlled trials, and performed a subgroup analysis on placeboâcontrolled versus open studies in an attempt to minimise allocation and performance bias. Many of the included studies were older (published between 1973 and 1990), and most did not report on many sources of potential bias, such as how the randomisation sequence was generated, and whether participant outcome was assessed by individuals who were blinded to the given intervention. Therefore, we scored many potential sources as unclear risk of bias, as can be seen inÂ <a href="#CD001245-fig-0002">Figure 2</a>Â andÂ <a href="#CD001245-fig-0003">Figure 3</a>. Luckily, the studies assessed with several sources of unclear risk were small, and in total, comprised about 10% of all included participants. The majority of the included participants originated from four studies (<a href="./references#CD001245-bbs2-0004" title="HillmanJ , FridrikssonS , NillsonO , YuZ , SavelandH , JakobssonKE . Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. Journal of Neurosurgery2002;97:771-8. [MEDLINE: 12405362]">Hillman 2002</a>;Â <a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>;Â <a href="./references#CD001245-bbs2-0008" title="RoosY , for the STAR-study group. Antifibrinolytic treatment in aneurysmal subarachnoid haemorrhage: a randomized placebo-controlled trial. Neurology2000;54:77-82. [MEDLINE: 10636129]">Roos 2000a</a>;Â <a href="./references#CD001245-bbs2-0011" title="VermeulenM , LindsayKW , MurrayGD , CheahF , HijdraA , MuizelaarJP , et al. Antifibrinolytic treatment in subarachnoid hemorrhage. New England Journal of Medicine1984;311:432-7. [MEDLINE: 1984270539]">Vermeulen 1984</a>). Three of these studies, comprising 65% of all data, were rated as low risk of bias for all sources, except for performance bias inÂ <a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>Â (<a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>;Â <a href="./references#CD001245-bbs2-0008" title="RoosY , for the STAR-study group. Antifibrinolytic treatment in aneurysmal subarachnoid haemorrhage: a randomized placebo-controlled trial. Neurology2000;54:77-82. [MEDLINE: 10636129]">Roos 2000a</a>;Â <a href="./references#CD001245-bbs2-0011" title="VermeulenM , LindsayKW , MurrayGD , CheahF , HijdraA , MuizelaarJP , et al. Antifibrinolytic treatment in subarachnoid hemorrhage. New England Journal of Medicine1984;311:432-7. [MEDLINE: 1984270539]">Vermeulen 1984</a>). InÂ <a href="./references#CD001245-bbs2-0004" title="HillmanJ , FridrikssonS , NillsonO , YuZ , SavelandH , JakobssonKE . Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. Journal of Neurosurgery2002;97:771-8. [MEDLINE: 12405362]">Hillman 2002</a>, many potential sources of bias could not be scored and were unclear, such as sequence generation, allocation concealment, and blinded outcome assessment. Moreover, 15% of included participants were later excluded from the analysis, and the baseline characteristics and outcomes of these participants were not reported. We included this study in the subgroup analysis with ischaemia prevention and treatment duration &lt; 72 hours, in which the much larger and methodologically sound study ofÂ <a href="./references#CD001245-bbs2-0007" title="GermansMR , PostR , CoertBA , RinkelGJE , VandertopWP , VerbaanD . Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials2013;14(143):1-6. [DOI: 10.1186/1745-6215-14-143]PostR , GermansMR , VandertopWP , VerbaanD , on behalf of the ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage: a randomised controlled clinical trial. Lancet2021;397(10269):112-8. TjerkstraMA , PostR , GermansMR , VergouwenMD , JellemaK , KootRW , et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. Neurology 2022 October 20 [Epub ahead of print]. [DOI: 10.1212/WNL.0000000000201160]">Post Â 2021</a>Â was also included. Because the latter study showed no large changes in effect on primary outcomes compared toÂ <a href="./references#CD001245-bbs2-0004" title="HillmanJ , FridrikssonS , NillsonO , YuZ , SavelandH , JakobssonKE . Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. Journal of Neurosurgery2002;97:771-8. [MEDLINE: 12405362]">Hillman 2002</a>,Â and because heterogeneity between studies was probably not important for poor outcome (IÂ² 33%;Â <a href="./references#CD001245-fig-0006" title="">Analysis 1.1</a>); and death from all causes (IÂ² 0%;Â <a href="./references#CD001245-fig-0008" title="">Analysis 1.3</a>), we assume that the results of this subgroup are trustworthy. </p> <p>Visual inspection of the funnel plots for death from all causes at end of followâupÂ (<a href="#CD001245-fig-0004">Figure 4</a>), and rebleeding reported at end of followâup (<a href="#CD001245-fig-0005">Figure 5</a>), revealed a potential publication bias, with a lack of small studies showing a harmful effect (RR &gt; 1) of antifibrinolytic treatment. We did not do a statistical analysis on these plots, due to the relatively small number of studies. Because several large randomised studies have been performed, the influence of small studies with negative results that were not published would not have changed the overall estimate of death or rebleeding after treatment with antifibrinolytic therapy.Â  </p> </section> <section id="CD001245-sec-0062"> <h3 class="title" id="CD001245-sec-0062">Potential biases in the review process</h3> <p>We searched all major medical electronic databases and other sources, using sensitive and validated search strategies. However, it is possible that we did not find all relevant publications. Furthermore, we only included studies that were published in medical literature and did not search the grey literature, such as government reports and unpublished information. Although all included trials met the predefined inclusion criteria, the studies differed considerably in participant selection, disease severity at baseline, start and duration of treatment, dosage and type of trial medication, classification of events, outcome assessment, and duration of followâup. This clinical heterogeneity may, in part, account for the statistical heterogeneity found in the analyses on rebleeding and delayed cerebral ischaemia. The process of selecting eligible studies and assessing sources of bias in the latest version of this review were not performed by the same assessors as in previous versions. However, one of the assessors in the current version was also an assessor in the previous version (MRG), which should have reduced interobserver variability, and therefore, reduced observer bias. </p> </section> <section id="CD001245-sec-0063"> <h3 class="title" id="CD001245-sec-0063">Agreements and disagreements with other studies or reviews</h3> <p>Our results are similar to the results from the most recent metaâanalysis (<a href="./references#CD001245-bbs2-0042" title="RenJ , QianD , WuJ , NiL , QianW , ZhaoG , et al. Safety and efficacy of tranexamic acid in aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials. Forntiers in Neurology2021;12:1-10. [PMID: 35140671]">Ren 2021</a>). <a href="./references#CD001245-bbs2-0042" title="RenJ , QianD , WuJ , NiL , QianW , ZhaoG , et al. Safety and efficacy of tranexamic acid in aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials. Forntiers in Neurology2021;12:1-10. [PMID: 35140671]">Ren 2021</a>Â included all randomised controlled trials included in the present update, exceptÂ <a href="./references#CD001245-bbs2-0003" title="GirvinJP . The use of antifibrinolytic agents in the preoperative treatment of ruptured intracranial aneurysms. Transactions of the American Neurological Association1973;98:150-2. [MEDLINE: 1974127393]">Girvin 1973</a>.Â Our results are also comparable withÂ <a href="./references#CD001245-bbs2-0027" title="GaberelT , MagheruC , EmeryE , DerlonJM . Antifibrinolytic therapy in the management of aneurismal subarachnoid hemorrhage revisited. A meta-analysis. Acta Neurochirurgica2012;154(1):1-9. [PMID: 22002504]">Gaberel 2012</a>,Â in which all studies compared antifibrinolytic treatment with control treatment,Â including retrospective analyses, and studies with historical control groups. Retrospective analyses are known to be much more susceptible to selection and reporting bias, since the decision to treat a person is made subjectively. <a href="./references#CD001245-bbs2-0027" title="GaberelT , MagheruC , EmeryE , DerlonJM . Antifibrinolytic therapy in the management of aneurismal subarachnoid hemorrhage revisited. A meta-analysis. Acta Neurochirurgica2012;154(1):1-9. [PMID: 22002504]">Gaberel 2012</a>Â did not compare placeboâcontrolled versus open studies, which is another potential source of bias, since all outcomes, except for death, are made on subjective clinical grounds, and can be easily biased when the outcome assessor is not blinded to the treatment given.Â  </p> <p>We only included randomised clinical trials in our review, and performed several sensitivity analyses, which should yield less biased results. Since most studies did not describe whether outcomes were assessed by a blinded outcome assessor, sensitivity analyses were essential. Despite the fact that all study authors reported that confirmation of rebleeding was investigated, in many cases, the diagnosis of rebleed was confirmed by examination of the CSF. Because CSF examination is an unreliable test to confirm rebleeding, we were not always able to prove the diagnosis of rebleeding (<a href="./references#CD001245-bbs2-0051" title="VermeulenM , vanGijnJ , BlijenbergBG . Spectrophotometric analysis of CSF after subarachnoid hemorrhage: limitations in the diagnosis of rebleeding. Neurology1983;33:112-4. [MEDLINE: 1983089354]">Vermeulen 1983</a>). Therefore, we decided to perform sensitivity analyses on reported versus confirmed (with confirmatory evidence on CT scan or at autopsy) rebleeding, cerebral ischaemia, and hydrocephalus. These different analyses showed similar results, so lack of confirmatory evidence of these complications appears to be of minor importance in our analyses. The analyses we performed on trials with a control treatment compared with those given placebo treatment showed similar reducing effects of antifibrinolytic treatment on rebleeding, and similar increasing effects on delayed cerebral ischaemia, whereas, hydrocephalus trials with a control treatment showed a tendency towards a beneficial effect compared with trials with placebo treatment, demonstrating a tendency towards increased hydrocephalus rates.Â  </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001245-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/urn:x-wiley:14651858:media:CD001245:CD001245-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA overview of updated search (December 2012 to May 2022)" data-id="CD001245-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_t/tCD001245-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA overview of updated search (December 2012 to May 2022)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/full#CD001245-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001245-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/urn:x-wiley:14651858:media:CD001245:CD001245-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD001245-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_t/tCD001245-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/full#CD001245-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001245-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/urn:x-wiley:14651858:media:CD001245:CD001245-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD001245-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_t/tCD001245-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/full#CD001245-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001245-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/urn:x-wiley:14651858:media:CD001245:CD001245-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of included trials assessing case fatality" data-id="CD001245-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_t/tCD001245-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of included trials assessing case fatality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/full#CD001245-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001245-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/urn:x-wiley:14651858:media:CD001245:CD001245-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of included trials assessing rebleeding" data-id="CD001245-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_t/tCD001245-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of included trials assessing rebleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/full#CD001245-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001245-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/urn:x-wiley:14651858:media:CD001245:CD001245-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 1: Poor outcome (death, vegetative, or (moderate) severe disability) at end of followâup: open versus blind studies" data-id="CD001245-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_t/tCD001245-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 1: Poor outcome (death, vegetative, or (moderate) severe disability) at end of followâup: open versus blind studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/references#CD001245-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001245-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/urn:x-wiley:14651858:media:CD001245:CD001245-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 2: Poor outcome (death, vegetative, or (moderate) severe disability) at end of followâup: trials with and without ischaemia prevention, according to treatment duration" data-id="CD001245-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_t/tCD001245-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 2: Poor outcome (death, vegetative, or (moderate) severe disability) at end of followâup: trials with and without ischaemia prevention, according to treatment duration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/references#CD001245-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001245-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/urn:x-wiley:14651858:media:CD001245:CD001245-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 3: Death from all causes at end of followâup: open versus blind studies" data-id="CD001245-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_t/tCD001245-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 3: Death from all causes at end of followâup: open versus blind studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/references#CD001245-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001245-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/urn:x-wiley:14651858:media:CD001245:CD001245-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 4: Death from all causes at end of followâup: trials with and without ischaemia prevention, according to treatment duration" data-id="CD001245-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_t/tCD001245-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 4: Death from all causes at end of followâup: trials with and without ischaemia prevention, according to treatment duration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/references#CD001245-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001245-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/urn:x-wiley:14651858:media:CD001245:CD001245-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 5: Rebleeding reported at end of followâup: open versus blind studies" data-id="CD001245-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_t/tCD001245-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 5: Rebleeding reported at end of followâup: open versus blind studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/references#CD001245-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001245-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/urn:x-wiley:14651858:media:CD001245:CD001245-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 6: Confirmed rebleeding at end of followâup (sensitivity analysis): open versus blind studies" data-id="CD001245-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_t/tCD001245-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 6: Confirmed rebleeding at end of followâup (sensitivity analysis): open versus blind studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/references#CD001245-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001245-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/urn:x-wiley:14651858:media:CD001245:CD001245-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 7: Rebleeding reported at end of followâup: trials with and without ischaemia prevention, according to treatment duration" data-id="CD001245-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_t/tCD001245-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 7: Rebleeding reported at end of followâup: trials with and without ischaemia prevention, according to treatment duration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/references#CD001245-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001245-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/urn:x-wiley:14651858:media:CD001245:CD001245-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 8: Delayed cerebral ischaemia reported at end of followâup: open versus blind studies" data-id="CD001245-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_t/tCD001245-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 8: Delayed cerebral ischaemia reported at end of followâup: open versus blind studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/references#CD001245-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001245-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/urn:x-wiley:14651858:media:CD001245:CD001245-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 9: Confirmed cerebral ischaemia at end of followâup (sensitivity analysis): open versus blind studies" data-id="CD001245-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_t/tCD001245-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 9: Confirmed cerebral ischaemia at end of followâup (sensitivity analysis): open versus blind studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/references#CD001245-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001245-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/urn:x-wiley:14651858:media:CD001245:CD001245-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 10: Delayed cerebral ischaemia reported at end of followâup: trials with and without ischaemia prevention, according to treatment duration" data-id="CD001245-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_t/tCD001245-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 10: Delayed cerebral ischaemia reported at end of followâup: trials with and without ischaemia prevention, according to treatment duration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/references#CD001245-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001245-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/urn:x-wiley:14651858:media:CD001245:CD001245-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 11: Hydrocephalus reported at end of followâup: open versus blind studies" data-id="CD001245-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_t/tCD001245-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 11: Hydrocephalus reported at end of followâup: open versus blind studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/references#CD001245-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001245-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/urn:x-wiley:14651858:media:CD001245:CD001245-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 12: Confirmed hydrocephalus at end of followâup (sensitivity analysis): open versus blind studies" data-id="CD001245-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_t/tCD001245-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 12: Confirmed hydrocephalus at end of followâup (sensitivity analysis): open versus blind studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/references#CD001245-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001245-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/urn:x-wiley:14651858:media:CD001245:CD001245-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 13: Hydrocephalus reported at end of followâup: trials with and without ischaemia prevention, according to treatment duration" data-id="CD001245-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_t/tCD001245-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 13: Hydrocephalus reported at end of followâup: trials with and without ischaemia prevention, according to treatment duration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/references#CD001245-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/media/CDSR/CD001245/image_n/nCD001245-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001245-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign=""> <p><b>Antifibrinolytic therapy compared with standard care for aneurysmal subarachnoid haemorrhage</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Patient or population</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>adults with aneurysmal subarachnoid haemorrhage (SAH)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Setting</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>hospital</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>antifibrinolytic (AF) therapy</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>standard care</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Quality of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Poor outcome</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.03 (0.94 to 1.13)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2359 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>++++ (high)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At a range of three to six months; low heterogeneity (IÂ² = 0%) between studies and and subgroups </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.02 (0.90 to 1.16)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2717 (11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>++++ (high)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At a range of three weeks to six months; low heterogeneity (IÂ² = 4%) between studies and and subgroups </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rebleeding</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.65 (0.47 to 0.91)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2717 (11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+++ (moderate)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity (IÂ² = 59%) between studies and and subgroups</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Delayed cerebral ischemia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.27 (1.00 to 1.62)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2484 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+++ (moderate)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity (IÂ² = 52%) between studies is largely based on early studies that did not implement ischemia preventive therapy. This resulted in a relatively high OR. Recent studies have implemented ischemia prevention as standard SAH care. It is likely that future research will result in a lower OR for DCI </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hydrocephalus</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.09 (0.99 to 1.20)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1992 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>++++ (high)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low heterogeneity (IÂ² = 0%) between studies and and subgroups</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><b>CI:</b> confidence interval; <b>DCI</b> : delayed cerebral ischemia; <b>OR</b> : odds ratio; <b>RR:</b> risk ratio </p> <p><sup>a</sup>Quality reduced due to inconsistencies in results<br/><sup>b</sup>Quality reduced due to inconsistency and indirectness </p> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High quality</b>: further research is very unlikely to change our confidence in the estimate of effect. </p> <p><b>Moderate quality</b>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.Â  </p> <p><b>Low quality</b>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> <p><b>Very low quality</b>: we are uncertain about the estimate. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/full#CD001245-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001245-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span>Â <span class="table-title">Antifibrinolytic treatment versus control treatment with or without placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Poor outcome (death, vegetative, or (moderate) severe disability) at end of followâup: open versus blind studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.94, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Trials with control treatment (open studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.81, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Trials with placebo treatment (blind studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1041</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.93, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Poor outcome (death, vegetative, or (moderate) severe disability) at end of followâup: trials with and without ischaemia prevention, according to treatment duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.94, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Trials without ischaemia prevention, treatment duration &gt; 72 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.86, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Trials with ischaemia prevention, treatment duration &gt; 72 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.91, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Trials with ischaemia prevention, treatment duration &lt; 72 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.81, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Death from all causes at end of followâup: open versus blind studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.90, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Trials with control treatment (open studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.74, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Trials with placebo treatment (blind studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.87, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Death from all causes at end of followâup: trials with and without ischaemia prevention, according to treatment duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.90, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Trials without ischaemia prevention, treatment duration &gt; 72 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>937</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.78, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Trials with ischaemia prevention, treatment duration &gt; 72 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.79, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Trials with ischaemia prevention, treatment duration &lt; 72 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.84, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Rebleeding reported at end of followâup: open versus blind studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.47, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Trials with control treatment (open studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.35, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Trials with placebo treatment (blind studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.43, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Confirmed rebleeding at end of followâup (sensitivity analysis): open versus blind studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.34, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Trials with control treatment (open studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.25, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Trials with placebo treatment (blind studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.25, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Rebleeding reported at end of followâup: trials with and without ischaemia prevention, according to treatment duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.47, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Trials without ischaemia prevention, treatment duration &gt; 72 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>937</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.47, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Trials with ischaemia prevention, treatment duration &gt; 72 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.42, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Trials with ischaemia prevention, treatment duration &lt; 72 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.13, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Delayed cerebral ischaemia reported at end of followâup: open versus blind studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.00, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Trials with control treatment (open studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.88, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Trials with placebo treatment (blind studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1041</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.87, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Confirmed cerebral ischaemia at end of followâup (sensitivity analysis): open versus blind studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.90, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Trials with control treatment (open studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.56, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Trials with placebo treatment (blind studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.82, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Delayed cerebral ischaemia reported at end of followâup: trials with and without ischaemia prevention, according to treatment duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.00, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Trials without ischaemia prevention, treatment duration &gt; 72 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.30, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Trials with ischaemia prevention, treatment duration &gt; 72 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.75, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 Trials with ischaemia prevention, treatment duration &lt; 72 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.83, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Hydrocephalus reported at end of followâup: open versus blind studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.99, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Trials with control treatment (open studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.66, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Trials with placebo treatment (blind studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1041</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.95, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Confirmed hydrocephalus at end of followâup (sensitivity analysis): open versus blind studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.99, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Trials with control treatment (open studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.97, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Trials with placebo treatment (blind studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.87, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Hydrocephalus reported at end of followâup: trials with and without ischaemia prevention, according to treatment duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.99, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Trials without ischaemia prevention, treatment duration &gt; 72 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.74, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Trials with ischaemia prevention, treatment duration &gt; 72 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.87, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.3 Trials with ischaemia prevention, treatment duration &lt; 72 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.97, 1.21]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span>Â <span class="table-title">Antifibrinolytic treatment versus control treatment with or without placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001245.pub3/references#CD001245-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001245.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD001245-note-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD001245-note-0012">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="fa#CD001245-note-0010">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="fr#CD001245-note-0011">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="ko#CD001245-note-0008">íêµ­ì´</a> </li> <li class="section-language"> <a class="" href="ms#CD001245-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD001245-note-0007">Ð ÑÑÑÐºÐ¸Ð¹</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001245-note-0005">ç®ä½ä¸­æ</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD001245-note-0006">ç¹é«ä¸­æ</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright Â© 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">Â Â Facebook</a> <a class="a2a_button_x share-button">Â Â X(Twitter)</a> <a class="a2a_button_whatsapp share-button">Â Â WhatsApp</a> <a class="a2a_dd share-button">Â Â View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001245\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001245\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001245\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001245\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001245\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001245\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001245\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001245\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001245\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001245\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001245\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001245\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001245\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001245\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001245\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001245\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001245\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001245\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001245.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001245.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">EspaÃ±ol</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">ÙØ§Ø±Ø³Û</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">FranÃ§ais</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">à¤¹à¤¿à¤¨à¥à¤¦à¥</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">æ¥æ¬èª</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">íêµ­ì´</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">PortuguÃªs</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Ð ÑÑÑÐºÐ¸Ð¹</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">RomÃ¢nÄ</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">à®¤à®®à®¿à®´à¯</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">à¸ à¸²à¸©à¸²à¹à¸à¸¢</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">ç¹é«ä¸­æ</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">ç®ä½ä¸­æ</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001245.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001245.pub3/full/es">EspaÃ±ol</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001245.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717082177"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001245.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717082181"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001245.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918daf3d8bd1936e',t:'MTc0MDcxNzA4Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 